Andrew Advani

MD, FRCP, PhD, MBChB(Hons), BSc

Scientist

Biography

Dr. Andrew Advani is a Staff Endocrinologist and Associate Professor/Clinician Scientist at the Keenan Research Centre for Biomedical Science, St. Michael’s Hospital and Department of Medicine at University  of Toronto. His research program is focused on the discovery and development of new treatments for diabetic kidney disease and related cardiovascular and kidney diseases. Dr. Advani holds the Keenan Chair in Medicine at St. Michael’s Hospital and University of Toronto.

Despite current treatments, people with diabetes continue to be affected by the long-term consequences of the disease. These long-term consequences include kidney disease, eye disease, nerve disease and heart disease. Kidney disease due to diabetes is the most common cause of kidney failure requiring treatment with dialysis or a kidney transplant and people with kidney disease are much more likely to die from heart disease. The Advani Lab is committed to conducting research on the causes of kidney disease in diabetes and on the links between kidney disease and heart disease. Through this research, Dr. Advani aims to develop new and better treatments for diabetes to reduce the burden of the condition on the millions of people affected.

Dr. Advani completed his medical training at the University of Edinburgh (UK) in 1996 and his PhD at Newcastle University (UK) in 2003. He was appointed on Staff at St. Michael’s Hospital in 2008. He is a Fellow of the Royal College of Physicians (UK). He has over 90 publications and has won awards from the British Hypertension Society, Royal College of Physicians (UK), Diabetes Canada, Canadian Society of Endocrinology and Metabolism and Banting and Best Diabetes Centre.

In his clinical practice, Dr. Advani provides care for people living with diabetes, especially young adults living with Type 1 diabetes. Through this work, Dr. Advani’s research program is also examining innovative ways for improving the lives of young people living with diabetes.

The Advani Lab is always interested in hearing from highly motivated and accomplished individuals interested in post-doctoral fellowships or graduate studentships.

Recent Publications

  1. Kaur, H, Advani, A. The study of single cells in diabetic kidney disease. J Nephrol. 2021; :. doi: 10.1007/s40620-020-00964-1. PubMed PMID:33476038 .
  2. Batchu, SN, Kaur, H, Yerra, VG, Advani, SL, Kabir, MG, Liu, Y et al.. Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19. Diabetes. 2021;70 (3):759-771. doi: 10.2337/db20-0765. PubMed PMID:33310740 .
  3. Advani, A. Acute Kidney Injury: A Bona Fide Complication of Diabetes. Diabetes. 2020;69 (11):2229-2237. doi: 10.2337/db20-0604. PubMed PMID:33082271 .
  4. Pritlove, C, Markowitz, B, Mukerji, G, Advani, A, Parsons, JA. Experiences and perspectives of the parents of emerging adults living with type 1 diabetes. BMJ Open Diabetes Res Care. 2020;8 (1):. doi: 10.1136/bmjdrc-2019-001125. PubMed PMID:33004400 PubMed Central PMC7534673.
  5. Batchu, SN, Yerra, VG, Liu, Y, Advani, SL, Klein, T, Advani, A et al.. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans. Int J Mol Sci. 2020;21 (16):. doi: 10.3390/ijms21165756. PubMed PMID:32796688 PubMed Central PMC7460951.
  6. Doria, A, Galecki, AT, Spino, C, Pop-Busui, R, Cherney, DZ, Lingvay, I et al.. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020;382 (26):2493-2503. doi: 10.1056/NEJMoa1916624. PubMed PMID:32579810 PubMed Central PMC7375708.
  7. Abdalla, M, Abdalla, M, Siddiqi, FS, Geldenhuys, L, Batchu, SN, Tolosa, MF et al.. A common glomerular transcriptomic signature distinguishes diabetic kidney disease from other kidney diseases in humans and mice. Curr Res Transl Med. 2020;68 (4):225-236. doi: 10.1016/j.retram.2020.05.001. PubMed PMID:32499177 .
  8. Mahmud, FH, Clarke, ABM, Joachim, KC, Assor, E, McDonald, C, Saibil, F et al.. Screening and Treatment Outcomes in Adults and Children With Type 1 Diabetes and Asymptomatic Celiac Disease: The CD-DIET Study. Diabetes Care. 2020;43 (7):1553-1556. doi: 10.2337/dc19-1944. PubMed PMID:32345653 .
  9. Sanwal, R, Khosraviani, N, Advani, SL, Advani, A, Lee, WL. The Endothelial Barrier Is not Rate-limiting to Insulin Action in the Myocardium of Male Mice. Endocrinology. 2020;161 (4):. doi: 10.1210/endocr/bqaa029. PubMed PMID:32103251 PubMed Central PMC7069687.
  10. Connelly, KA, Zhang, Y, Desjardins, JF, Nghiem, L, Visram, A, Batchu, SN et al.. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19 (1):13. doi: 10.1186/s12933-020-0994-y. PubMed PMID:32035482 PubMed Central PMC7007658.
Search PubMed

Affiliations & Other Activities

  • Staff Endocrinologist/Clinician Scientist, Division of Endocrinology, St. Michael’s Hospital
  • Associate Professor/Clinician Scientist, Department of Medicine, University of Toronto
X